• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Creative Medical Technology Holdings Inc. (Amendment)

    2/11/22 9:11:24 PM ET
    $CELZ
    Finance: Consumer Services
    Finance
    Get the next $CELZ alert in real time by email
    SC 13G/A 1 celz_sc13ga-123121.htm AMENDMENT TO SC 13G
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     
    Creative Medical Technology Holdings, Inc.

    (Name of Issuer)

     

     

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

     

     

    22529Y309

    (CUSIP Number)

     

     
    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     
     
      Page 2 of 8

     

    CUSIP No.  22529Y309    

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

     

    0

     
    6

    SHARED VOTING POWER

     

    363,000 shares of Common Stock issuable upon exercise of Public Warrants(1)

    85,458 shares of Common Stock issuable upon exercise of Warrants(1)

     
    7

    SOLE DISPOSITIVE POWER

     

    0

     
    8

    SHARED DISPOSITIVE POWER

     

    363,000 shares of Common Stock issuable upon exercise of Public Warrants(1)

    85,458 shares of Common Stock issuable upon exercise of Warrants(1)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    363,000 shares of Common Stock issuable upon exercise of Public Warrants(1)

    85,458 shares of Common Stock issuable upon exercise of Warrants(1)

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.99%(1)(2)

     
    12

    TYPE OF REPORTING PERSON

     

    IA, PN

     
             

     

    (1)    As more fully described in Item 4, both the Public Warrants and Warrants are subject to blockers of 4.99%. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by each such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    (2)    Based on 6,327,348 shares of Common Stock outstanding as of December 2, 2021, as set forth in the Issuer’s Form 424B4 filed with the Securities and Exchange Commission on December 6, 2021.

     

     

     

     
      Page 3 of 8

     

    CUSIP No.  22529Y309    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

     

    0

     
    6

    SHARED VOTING POWER

     

    363,000 shares of Common Stock issuable upon exercise of Public Warrants(1)

    85,458 shares of Common Stock issuable upon exercise of Warrants(1)

     
    7

    SOLE DISPOSITIVE POWER

     

    0

     
    8

    SHARED DISPOSITIVE POWER

     

    363,000 shares of Common Stock issuable upon exercise of Public Warrants(1)

    85,458 shares of Common Stock issuable upon exercise of Warrants(1)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    363,000 shares of Common Stock issuable upon exercise of Public Warrants(1)

    85,458 shares of Common Stock issuable upon exercise of Warrants(1)

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.99%(1)(2)

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     
             

     

    (1)    As more fully described in Item 4, both the Public Warrants and Warrants are subject to blockers of 4.99%. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by each such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    (2)    Based on 6,327,348 shares of Common Stock outstanding as of December 2, 2021, as set forth in the Issuer’s Form 424B4 filed with the Securities and Exchange Commission on December 6, 2021.

     

     
      Page 4 of 8

     

    CUSIP No.  22529Y309    

     

    1

    NAME OF REPORTING PERSONS

    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

     

    0

     
    6

    SHARED VOTING POWER

     

    363,000 shares of Common Stock issuable upon exercise of Public Warrants(1)

    85,458 shares of Common Stock issuable upon exercise of Warrants(1)

     
    7

    SOLE DISPOSITIVE POWER

     

    0

     
    8

    SHARED DISPOSITIVE POWER

     

    363,000 shares of Common Stock issuable upon exercise of Public Warrants(1)

    85,458 shares of Common Stock issuable upon exercise of Warrants(1)

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    363,000 shares of Common Stock issuable upon exercise of Public Warrants(1)

    85,458 shares of Common Stock issuable upon exercise of Warrants(1)

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.99%(1)(2)

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     
             

     

    (1)    As more fully described in Item 4, both the Public Warrants and Warrants are subject to blockers of 4.99%. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by each such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

     

    (2)    Based on 6,327,348 shares of Common Stock outstanding as of December 2, 2021, as set forth in the Issuer’s Form 424B4 filed with the Securities and Exchange Commission on December 6, 2021.

     

     
      Page 5 of 8

     

    CUSIP No.  22529Y309    

     

    Item 1(a).   Name of Issuer:                                                         Creative Medical Technology Holdings, Inc. (the “Issuer”)
         
         
    Item 1(b).   Address of Issuer’s Principal Executive Offices:  211 E Osborn Road, Phoenix, AZ 85012
         
         
    Item 2(a).  

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

                                                    
         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019
         
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, par value $0.001 per share (“Common Stock”)
         
         
    Item 2(e).   CUSIP Number: 22529Y309
         
         

     

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     
      Page 6 of 8

     

    CUSIP No.  22529Y309    

     

           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
     

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 6,327,348 shares of Common Stock outstanding as of December 2, 2021, as set forth in the Issuer’s Form 424B4 filed with the Securities and Exchange Commission on December 6, 2021.

     

    Pursuant to the terms of the securities purchase agreement entered into between the Fund and the Issuer, the Fund purchased “Public Warrants.” The Fund previously owned “Warrants” via a separate securities purchase agreement. The Reporting Persons are subject to blockers and cannot exercise the Warrants or Public Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock. The percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise any of the Warrants or Public Warrants.

     

     

     

     
      Page 7 of 8

     

    CUSIP No.  22529Y309    

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒
       
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:   February 11, 2022

     
     

      

    Altium Capital Management, LP

     
           
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: CEO  
           
           
     

    Altium Growth Fund, LP

     

    By: Altium Growth GP, LLC

    Its: General Partner

     
         
      Signature: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member of Altium Growth GP, LLC  
           
       
      Altium Growth GP, LLC  
           
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member  

     

     
      Page 8 of 8

     

    EXHIBIT INDEX

     

     

    EXHIBIT 1:        Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

    Members of Group

     

     

     

    Get the next $CELZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELZ

    DatePrice TargetRatingAnalyst
    2/25/2022$10.00Buy
    Roth Capital
    More analyst ratings

    $CELZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

    PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) (the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company originally issued in March 2025, at their current exercise price of $3.75 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-286346). The aggregate

    10/29/25 9:00:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    Creative Medical Technology Holdings Issues Letter to Shareholders

    PHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today issued a Letter to Shareholders from Timothy Warbington, Co-Founder and Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a landmark year for Creative Medical. With the support of the most comprehensive clinical, intellectual, and technological foundation in our Company's history, we have evolved from proof-of-concept to clinical trials in support of our mission to develop breakthrough regenerative stem cell therapies across multiple indications. At the

    10/27/25 8:15:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

    PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on being awarded the 2025 Nobel Prize in Physiology or Medicine for foundational discoveries in peripheral immune tolerance and the biology of regulatory T cells (Tregs). Their work—including the identification of Tregs and the central role of FOXP3—reshaped modern immunology and catalyzed new treatment strategies across autoimmunity, transplantation, and cancer. In parallel wi

    10/7/25 9:15:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Finger Michael H. sold $8,062 worth of shares (1,500 units at $5.38), decreasing direct ownership by 81% to 351 units (SEC Form 4)

    4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)

    2/20/25 7:23:52 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Warbington Timothy

    4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)

    6/29/23 5:37:18 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 4: Warbington Timothy bought $9,862 worth of shares (25,000 units at $0.39), increasing direct ownership by 29% to 112,087 units

    4 - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Issuer)

    11/23/22 9:09:14 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Creative Medical Tech with a new price target

    Roth Capital initiated coverage of Creative Medical Tech with a rating of Buy and set a new price target of $10.00

    2/25/22 9:18:39 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    SEC Filings

    View All

    SEC Form DEF 14A filed by Creative Medical Technology Holdings Inc.

    DEF 14A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    10/30/25 6:11:46 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.

    10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    8/8/25 4:45:55 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.

    10-Q - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Filer)

    5/9/25 4:45:24 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Leadership Updates

    Live Leadership Updates

    View All

    Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

    PHOENIX, Ariz. , March 2, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ:CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced the appointment of Sahil Nock as the Company's Chief Commercial Officer, effective February 28, 2022. Mr. Nock brings to Creative Medical Technology more than 15 years of healthcare leadership experience in sales, marketing, and business development. He most recently served

    3/2/22 8:30:00 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    $CELZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Creative Medical Technology Holdings Inc. (Amendment)

    SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)

    5/26/23 10:23:18 AM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form SC 13G filed by Creative Medical Technology Holdings Inc.

    SC 13G - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)

    5/1/23 9:49:02 PM ET
    $CELZ
    Finance: Consumer Services
    Finance

    SEC Form SC 13G/A filed by Creative Medical Technology Holdings Inc. (Amendment)

    SC 13G/A - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (0001187953) (Subject)

    2/14/22 3:30:56 PM ET
    $CELZ
    Finance: Consumer Services
    Finance